

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Atty. Dkt. No.

Client Ref.

037003-0277113

1999-30-0310A

Applicant: BRASLAWSKY et al.

Appln. No.: 09/238,741

Filing Date: January 28, 1999

Date: May 24, 2004

Page 1 of 1

Examiner: Unassigned

Group Art Unit:
1642

U.S. PATENT DOCUMENTS

Examiner's Initials		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date if appropriate
	AR						
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						
	HR						
	IR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	No
LA	JR	WO 96/14339	05/1996	PCT	KULL et al.					
LA	KR	WO 99/66951	12/1999	PCT	HANSEN et al.					
	LR									
	MR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Volume and Pertinent Pages, etc.)

LA	NR	Demidem A, et al., "Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs," <i>Cancer Biotherapy & Radiopharmaceuticals</i> , 1997, 12(3):177-186.
	OR	Featherstone, "Bispecific antibodies: the new magic bullets," <i>Lancet</i> , 1996, 348: 536
	PR	Ghetie M, et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94: 7509-7514
	QR	Hartmann, et al., "Treatment of Hodgkin's disease with bispecific antibodies," <i>Annals of Oncology</i> 7 (Suppl 4), 1996, S143-S146
	RR	Kroesen, et al., "The role of apoptosis: a bispecific antibody-mediated T-cell cytotoxicity," <i>Br. J. Cancer</i> , 1996, 73(6): 721-727
	SR	Ring, et al., "Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens," <i>Cancer Immunology Immunotherapy</i> , 1994, 39: 41-48
	TR	Shan et al., "Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies," <i>Blood</i> , 1998, 91(5): 1644-1652
	UR	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity," <i>J. Immun.</i> , 1992, 148(9): 2918-2922
LA	VR	Snider et al., "Processing fate of protein antigen attached to IgD or MHC molecules on normal B lymphocytes using heterocrosslinked bispecific antibodies," <i>Molecular Immun.</i> , 1991, 28(7): 779-788

Examiner

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty. Ref. No.

Client Ref.
1999-30-0310A

037003-0277113

Applicant: BRASLAWSKY et al.

Appln. No.: 09/238,741

Filing Date: January 28, 1999

Examiner: L. Helms

Group Art Unit: 1642

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Date: July 7, 2004

Page 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)
LA	AR	5,830,698	Reff
BR			


FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		Abstract		Readily Available	
							Enclosed	No	Enclosed	No
LA	CR	WO 91 19515	12/1991	PCT	Shopes					
	DR									

OTHER (Including in this order: Author, Title, Periodical Name, Date, Volume, and Pertinent Pages)

LA	ER	Brennan M, et al., "Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments," <i>Science</i> , 1985, 229: 81-3.
	FR	Chaouchi N, et al., "B cell antigen receptor-mediated apoptosis. Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking," <i>J Immunol</i> , 1995, 154: 3096-104.
	GR	Clark EA, et al., "Role of the Bp35 cell surface polypeptide in human B-cell activation," <i>Proc Natl Acad Sci U S A</i> , 1985, 82: 1766-70.
	HR	Clark EA, et al., "Structure, function, and genetics of human B cell-associated surface molecules," <i>Adv Cancer Res</i> , 1989, 52: 81-149.
	IR	FitzGerald K, et al., "Improved tumour targeting by disulphide stabilized diabodies expressed in <i>Pichia pastoris</i> ," <i>Protein Eng</i> , 1997, 10: 1221-5.
	JR	Funakoshi S, et al., "Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas," <i>J Immunother Emphasis Tumor Immunol</i> , 1996, 19: 93-101.
	KR	Holder M, et al., "Engagement of CD20 suppresses apoptosis in germinal center B cells," <i>Eur. J. Immunol.</i> , 1995, 25: 3160-64.
	LR	Hooijberg E, et al., "Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model," <i>Cancer Res.</i> , 1995, 55: 840-6.
	MR	Jiang Liying et al., "Enhanced effector functions of dimeric forms of IDEC-C2B8 (rituximab)," <i>Blood</i> , 1999, 94(10):86a (Abstract No. 376).
	NR	Maloney DG, et al., "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma," <i>Blood</i> , 1994, 84: 2457-66.
	OR	Maloney et al., "IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma," <i>J Clin Oncol</i> , 1997, 15(10):3266.
	PR	McLaughlin et al., "IDEC-C2B (rituximab): clinical activity in clinically chemoresistant (CCRD) low-grade of follicular lymphoma (LG/F NHL) and in patients (pts) relapsing after anthracycline therapy (ANTRA-RX) of ABMT," <i>Proc. Am. Soc. Clin. Oncol.</i> , 1997, 16: 16a (Abstract 55)
	QR	McLaughlin et al., "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," <i>J Clin Oncol.</i> , 1998, 16(8):2825-33.
	RR	Merchant AM et al., "An efficient route to human bispecific IgG," <i>Nature Biotechnology</i> , 1998, 16(7):1087 (Abstract).
LA	SR	Newell MK, et al., "Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes," <i>Proc Natl Acad Sci U S A</i> , 1993, 90: 10459-63.

[Handwritten signature] 7/27/04



LA	TR	Press OW, et al., "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas," <i>Blood</i> , 1987, 69: 584-91.
	UR	Siegall CB, et al., "Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab') ₂ , and Fab' conjugated to Pseudomonas exotoxin," <i>Bioconj Chem</i> , 1992, 3: 302-7.
	VR	Tedder TF, et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16: 881-7.
	WR	Tedder TF, et al., "CD20: a regulator of cell-cycle progression of B lymphocytes," <i>Immunol Today</i> , 1994, 15: 450-4.
	XR	Valentine MA, et al., "Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40," <i>Eur J Immunol</i> , 1992, 22: 3141-8.
	YR	Varadarajan et al., "Conjugation of Phenyl Isothiocyanate Derivatives of Carborane to Antitumor Antibody and In Vivo Localization of Conjugates in Nude Mice," <i>Bioconj. Chem.</i> , 1991, 2: 102-110.
	ZR	Willner D, et al., "(6-Maleimidocaproyl)hydrazine of doxorubicin--a new derivative for the preparation of immunoconjugates of doxorubicin," <i>Bioconj Chem</i> , 1993, 4: 521-7.
WA	AAR	Wolff EA, et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice," <i>Cancer Res</i> , 1993, 53: 2560-5.

Examiner		Date Considered:	7/27/04
----------	--	------------------	---------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.